In this symposium from ERS 2018, Prof. Peter Cistulli highlights the effectiveness of Mandibular Advancement Device (MAD) therapy in the treatment of Obstructive Sleep Apnoea (OSA) and snoring*. In the second half (from 26:36), Prof. JeanClaude Meurice explores complianceoriented design in the Narval CC™ oral appliance. To learn more, visit https://ResMed.com/Narval

*Narval CC is indicated to treat adults with snoring or mild to moderate Obstructive Sleep Apnoea (OSA). In case of severe OSA, it is indicated after positive airway pressure (CPAP) therapy failure, noncompliance or refusal.